In the real world, the selection of a therapeutic modality like an antibody or peptide is often driven by a company's existing expertise and technology platform rather than a purely agnostic approach to finding the single best tool for a clinical problem. Organizations default to the tools in their toolbox.

The IGI simultaneously pursues two tracks: It targets monogenic diseases where cures are achievable now for immediate impact. In parallel, it invests in the foundational science needed to tackle highly complex diseases like Alzheimer's and solid tumors, building a portfolio for the long term.

Recent large financing rounds, like Soli's $200M Series C and Parabillus's $305M Series F, are predominantly for companies with proprietary discovery platforms rather than single-asset biotechs. This indicates investor confidence in technologies that can generate a pipeline of multiple future therapies, valuing repeatable innovation over individual drug candidates.

In a market favoring asset-centric biotech, Springtide VC remains focused on platform companies. This countercyclical strategy mitigates the binary risk of single-asset failure and allows for multiple "shots on goal" and diverse business models, such as partnerships or becoming a drug developer.

Augurex's CEO identified a major opportunity by noting that biomarker use in rheumatology was 10-15 years behind oncology. This "technology lag" between medical specialties signals a significant unmet need and a prime area for innovation, allowing proven concepts from one field to revolutionize another.

VC Claire Smith defines "Tech Bio" as a "tech-first" approach, where a novel hardware or software platform is the core innovation, which is then applied to solve biological problems. This contrasts with traditional biotech, which starts with a biological insight (like a target) and then uses a toolbox of existing technologies.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

The venture creation strategy for platform biotechs isn't about finding one blockbuster drug. It's a binary bet: either the underlying scientific platform is sound and can repeatedly generate many medicines, or the entire concept fails. There is no middle ground of succeeding with just one product from the platform.

All therapeutic discoveries fall into two types. The first is a biological insight, where the challenge is to find a way to drug it. The second is a technical advancement, like a new platform technology, where the challenge is to find the right clinical application for it. This clarifies a startup's core problem.